Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome

Tisagenlecleucel (tisa-cel) is a CD19(-)specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n = 25) who were treated with tisa-cel under non-cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Štach, Martin, Pytlík, Robert, Šmilauerová, Kristýna, Rychlá, Jana, Mucha, Martin, Musil, Jan, Koladiya, Abhishek, Nemec, Matěj, Petráčková, Martina, Kaštánková, Iva, Pecherková, Pavla, Šrámková, Lucie, Polgárová, Kamila, Trněný, Marek, Lesný, Petr, Vydra, Jan, Otáhal, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156917/
https://www.ncbi.nlm.nih.gov/pubmed/37151356
http://dx.doi.org/10.3389/pore.2023.1610914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156917/
https://www.ncbi.nlm.nih.gov/pubmed/37151356
http://dx.doi.org/10.3389/pore.2023.1610914

Ejemplares similares